ライフサイエンスコーパス: mGluR3

1 dy as a novel antipsychotic therapy aimed at mGluR3.

2 activates a group II metabotropic receptor, mGluR3.

3 re unable to discriminate between mGluR2 and mGluR3.

4 uman mGluR2 and is without activity at human mGluR3.

5 RGT cells transfected with human mGluR2 and mGluR3.

6 RGT cells transfected with human mGluR2 and mGluR3.

7 y mGluR2 (the proposed treatment target) and mGluR3.

8 aptic glutamate release by its action at the mGluR3 (a group II metabotropic glutamate receptor).

9 rated the antipsychotic efficacy of a mGluR2/mGluR3 agonist.

10 ceptor in the antipsychotic action of mGluR2/mGluR3 agonists.

11 increasing the duration of NAAG activity on mGluR3 and by reducing degradation into NAA and glutamat

12 Alignment between mGluR3 and mGluR2, a closely related group II receptor,

13 al control to two additional family members: mGluR3 and mGluR6.

14 s indicate distinct functions for mGluR2 and mGluR3 and suggest a dynamic regulation of mGluR3 by PP2

15 I metabotropic glutamate receptor subtype 3 (mGluR3) and suppresses glutamate release.

16 The normal expression levels of mGluR2, mGluR3, and GCP II were determined for 10 regions of the

17 etabotropic glutamate receptor (mGluR)-2 and mGluR3, and neuronal nitric oxide synthase.

18 group II metabotropic receptors (mGluR2 and mGluR3) are among different mechanisms that modulate pre

19 e type 1 metabotropic GluR (mGluR1), mGluR2, mGluR3, but not the mGluR5 subtype of G protein-linked m

20 d mGluR3 and suggest a dynamic regulation of mGluR3 by PP2C.

21 These findings indicate that mGluR2 (but not mGluR3) can selectively modulate GABAergic inhibition in

22 The minimal interacting domain of mGluR3 comprised residues 836-855.

23 The mGluR3 cytoplasmic C-terminal tail contains one phosphor

24 However, phosphorylation of the mGluR3 cytoplasmic tail at Ser-845 inhibits the interact

25 not PP1, PP2A, or PP2B, dephosphorylates the mGluR3 cytoplasmic tail in vitro.

26 The dephosphorylated form of the mGluR3 cytoplasmic tail, but not the equivalent region o

27 Unlike mGluR2, mGluR3 displays basal dynamics, which are Ca(2+)-depende

28 Increased GCP II expression and low mGluR3 expression in the dorsolateral prefrontal cortex

29 COMT) and in metabotropic glutamate receptor mgluR3 (GRM3), respectively, suggest that these genes in

30 , this cooperativity is asymmetric in mGluR2/mGluR3 heterodimers.

31 he only known specific endogenous agonist of mGluR3 in the mammalian brain.

32 metabotropic glutamate receptors mGluR2 and mGluR3 in the pathophysiology of schizophrenia.

33 onversely, activation of the Group II mGluR, mGluR3, induces long-term potentiation of electrical syn

34 oforms; however, among the mGluR family only mGluR3 interacted with PP2C.

35 hat the 50-aa C-terminal cytoplasmic tail of mGluR3 interacts specifically with protein phosphatase 2

36 mGluR3 interacts with PP2Calpha, beta, gamma, and delta

37 tment in rodents did not influence GCP II or mGluR3 levels.

38 parallel fiber synapses, while mGluR2 and/or mGluR3 may modulate mossy terminal function.

39 metabotropic glutamate receptors (mGluR2 and mGluR3) may control relapse of alcohol seeking, but prev

40 botropic glutamate receptor subunits mGluR1, mGluR3, mGluR4, mGluR5, and mGluR7.

41 Rs (mGluRs), signals for mGluR1, mGluR2, and mGluR3 mRNAs were low or undetectable, whereas mGluR4 an

42 lepticus did not alter expression of mGluR1, mGluR3, or mGluR5 mRNAs.

43 ncrease in GCP II protein and a reduction in mGluR3 protein in the dorsolateral prefrontal cortex in

44 Further, these data implicate the mGluR3 receptor in the antipsychotic action of mGluR2/mG

45 to distinguish the expression of mGluR2 and mGluR3 receptor proteins in schizophrenia and to quantif

46 ormed from NAA, and may be an agonist of the mGluR3 receptor.

47 ed to determine how activation of mGluR2 and mGluR3 receptors (Group II) might modulate visual respon

48 f LY354740 on IPSCs were not mimicked by the mGluR3-selective agonist N-acetyl-aspartyl-glutamate (NA

49 metabotropic glutamate receptors (mGluR2 and mGluR3) were suggested as targets for addiction treatmen

50 In contrast, mGluR3, whose activation inhibits adenylate cyclase but